Return to Listing

3 result(s) for RITUXAN

PI Name Protocol # Title
Andy Chen IRB00008906 GO27834: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of pinatuzumab vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and A Non Randomized phase Ib/II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-cell Non- Hodgkin’s Lymphoma
Stephen Spurgeon IRB00011800 Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Alexey Danilov STUDY00015069 A randomized phase III study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib alone in untreated older patients (≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080